Trial Profile
Reduced-dose efavirenz in patients with HIV-infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2015
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Nucleotide reverse transcriptase inhibitors
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 03 Dec 2015 New trial record